(Q33720943)

28 July 2017

1 reference

title

Symptomatic pharmacotherapy of migraine (English)

1 reference

28 July 2017

0 references

1 reference

Lobo BL

1

1 reference

28 July 2017

Cooke SC

series ordinal

2

1 reference

28 July 2017

Landy SH

series ordinal

3

1 reference

28 July 2017

publication date

1 July 1999

1 reference

28 July 2017

published in

Clinical Therapeutics

1 reference

28 July 2017

volume

21

1 reference

28 July 2017

issue

7

1 reference

28 July 2017

page(s)

1118-1130

1 reference

Burden of migraine: societal costs and therapeutic opportunities

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

Healthcare resource and lost labour costs of migraine headache in the US.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

1 reference

7 January 2021

Drug therapy of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

Interictal cortical hyperexcitability in migraine patients demonstrated with transcranial magnetic stimulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

Role and impact of over-the-counter medications in the management of headache

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

A correlation between severity of migraine and delayed gastric emptying measured by an epigastric impedance method

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

Comparative efficacy of chlorpromazine and meperidine with dimenhydrinate in migraine headache

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

Safety and efficacy of rectal prochlorperazine for the treatment of migraine in the emergency department

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

The efficacy of metoclopramide in the treatment of migraine headache

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

1 reference

7 January 2021

Serotonin 1D (5-HT1D) agonists and other agents in acute migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

Sumatriptan. An updated review of its use in migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

Opioids in headache treatment. Is there a role?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

Transformed migraine, analgesic rebound, and other chronic daily headaches

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980017-X

7 January 2021

10.1016/S0149-2918(00)80017-X

Identifiers

DOI

1 reference

28 July 2017

1 reference